07:38 AM EST, 11/05/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q3 non-GAAP earnings Wednesday of $0.78 per diluted share, up from $0.69 a year earlier.

Analysts surveyed by FactSet expected $0.68.

Net revenue for the quarter ended Sept. 30 was $4.48 billion, up from $4.33 billion a year earlier.

Analysts surveyed by FactSet expected $4.34 billion.

The company said it now expects 2025 non-GAAP earnings of $2.55 to $2.65 per share, compared with $2.50 to $2.65 previously. Analysts polled by FactSet expect $2.57.

Revenue for the current year is expected to be $16.8 billion to $17 billion, compared with its previous projection of $16.8 billion to $17.2 billion, the company said. Analysts surveyed by FactSet expect $16.83 billion.

Shares of the company were up nearly 10% in Wednesday's premarket activity.